

Crystal Research Issues Executive Informational Overview[®] on Applied DNA Sciences DNA Platform Technologies Provide Anti-Counterfeiting Security Solutions

STONY BROOK, N.Y., August 5, 2009/Marketwire/ - Applied DNA Sciences, Inc. (OTCBB: APDN) announced that Crystal Research Associates, LLC has issued an Executive Informational Overview[®] (EIO[®]) on APDN. The full report can be found at <http://www.crystalra.com>. Well-known and respected on Wall Street, Jeffrey Kraws, CEO of Crystal Research Associates (Crystal), has received some of the most prestigious awards in the industry and is a frequent guest on CNN, CNBC, MSNBC, Fox Business News and Bloomberg. He has been consistently ranked as one of the leading research analysts in the pharmaceutical sector on Wall Street (StarMine), and often cited for his expert opinion on important trends and financial direction relative to security, biotech, pharmaceuticals and other key sectors.

APDN provides [DNA-based security and authentication](#) solutions to identify originals and to help protect products, brands, and intellectual property from counterfeiting and diversion. Counterfeiting is one of the fastest growing pecuniary crimes, threatening jobs and business, and endangering public health and safety. The World Customs Organization estimated that the \$600 billion (2004) annual global trade in illegitimate goods is expected to double to \$1.2 trillion by 2014.

Driven by its two anti-counterfeiting security platforms, [SigNature[®] DNA](#) and [BioMaterial Genotyping[™]](#), APDN can service a multitude of industries including cash-in-transit, textiles and apparel, secure documents for military and homeland security, pharmaceuticals, wine, and other luxury items. Commercial applications across a broad spectrum of industries allow APDN to minimize revenue risk concentration and create a steady stream of income.

DNA is a form of forensic evidence trusted by police and recognized by courts around the world. APDN is the ONLY company making use of the complex codes embedded in botanical DNA as the ultimate solution to counterfeiting. Unlike holograms and RFIDs, APDN's patented SigNature DNA markers:

- cannot be copied or reverse engineered
- are forensic and offer absolute authentication
- are "green," safe and affordable

APDN has recently been selected to launch its SigNature DNA Anti-Counterfeiting Program for the UK and EU as the sole security platform to spearhead a multi-year, multi-million dollar contract.

About Crystal

Crystal is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal's unique and novel product, the EIO®, is free of investment ratings, target prices, and forward-looking financial models. The EIO® presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO® details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal has offices in New York City, Delray Beach, Montréal, and Toronto. Crystal has been compensated by the Company in cash of forty-two thousand five-hundred dollars and two-hundred thousand Warrants/Options for its services in creating this report, for updates, and for printing costs.

About APDN

APDN sells patented DNA security solutions to protect products, brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used to authenticate products in a unique manner that essentially cannot be copied. APDN also provides BioMaterial GenoTyping™ by detecting genomic DNA in natural materials to authenticate finished products. Both technologies protect brands and products in a wide range of industries and provide a forensic chain of evidence that can be used to prosecute perpetrators. To learn more, go to www.adnas.com where APDN routinely posts all press releases.

The statements made by APDN may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K, filed on December 16, 2008 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

Crystal Research Contacts:
Jeffrey J. Kraws and Karen B. Goldfarb
Crystal Research Associates, LLC
P: (609) 306-2274, F: (609) 395-9339

SOURCE Applied DNA Sciences, Inc.
INVESTOR RELATIONS: Debbie Bailey, 631-444-8090, fax: 631-444-8848/
MEDIA RELATIONS: Janice Meraglia, 631-444-6293
/FCMN Contact: info@adnas.com /
/Web site: <http://www.ADNAS.com> /